Search

Displaying results 4611 - 4620 of 10000 in total
  1. Drug

    Fibroblast growth factor-1

    go.drugbank.com/drugs/DB05599
    Investigational

    Mixtures: Le-Blen FGF Serum
  2. Drug

    Amobarbital

    go.drugbank.com/drugs/DB01351
    ApprovedIllicit

    Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)

  3. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    CTA018 will be the first drug with this novel dual mechanism of action to enter clinical development. … secretion which may be involved in the etiology of psoriasis.

  4. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    Development is assumed to have been discontinued. … In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline.

  5. Drug

    Becaplermin

    go.drugbank.com/drugs/DB00102
    ApprovedInvestigational

    Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae.

  6. Drug

    Bicifadine

    go.drugbank.com/drugs/DB04889
    Investigational

    Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain. … It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile.

  7. Target

    Mitochondrial potassium channel ATP-binding subunit

    go.drugbank.com/bio_entities/BE0003673
    TransporterHumans

    ATP-binding subunit of the mitochondrial ATP-gated potassium channel (mitoK(ATP)) (PubMed:31435016). Together with pore-forming subunit CCDC51/MITOK of the mitoK(ATP) channel, mediates ATP-dependent potassium currents across the mitochon...

    Synonyms: Mitochondrial sulfonylurea-receptor
  8. Drug

    XTL-6865

    go.drugbank.com/drugs/DB06058
    Investigational

    It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.

  9. Drug

    DL-Methylephedrine

    go.drugbank.com/drugs/DB11278
    Approved

    Methylephedrine is a sympathomimetic amine that appears in various over-the-counter cough and cold medications throughout the world [L2838], [L2839], [L2840]. … The abuse of methylephedrine-containing medications has been reported in Japan. Methylephedrine is not legally available in the United States, but has been identified in cases of drug abuse [L2836].

    Categories: Adrenergic alpha-2 Receptor Agonists
  10. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    The drug made it to phase III trials before abandoned due to increased stroke. … Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].